Aero Pump, Validose and Ursatec cooperate on digital augmentation of pump-based container closure systems for drug delivery

Marcel Botha, CEO of Validose stated: “The collaboration with two well established experts in nasal spray pump development and finished dosage manufacturing allows to support pharmaceutical partners over the whole product realisation cycle.”

During the next months, the three companies will establish the implementation of the Aero Pump/Ursatec spray devices into the Validose platform. In parallel, the combined technology will be applied to ongoing nasal spray development projects.

Dr. Andreas Bilstein, Managing Director of Ursatec commented: “The digital augmentation of our container closure systems utilising the Validose technology allows our partners to extend the use of nasal spray systems beyond their current application horizon as it allows patient centric control and dosage adjustment by the physician and prohibits drug misuse. Even in OTC application, additional digital features extend the patients product experience.”

Interested companies who would like to discuss the usage of the combined nasal spray application technology to enable a digital augmented nasal spray product are welcome to contact Aero Pump and Ursatec. Aero Pump and Ursatec are exhibiting at CPhI worldwide in Milan, from 9 – 11 November 2021 at booth number 6H80.

About Aero Pump

Aero Pump GmbH is one of the world’s leading manufacturers for pharmaceutical primary packaging. The company has constantly been growing since its foundation in 1976, and its products have been sold billions of times around the world. Aero Pump GmbH manufactures high precision application systems for the pharmaceutical and health care industry. The metered dose spray pumps and dropper systems are widely established in the market and are primarily used in nasal, ophthalmic, pulmonary, buccal and topical fields, suitable for preserved and preservative-free OTC and prescription drugs.

About Validose

Founded in 2017, Validose is committed to solving drug delivery personalization and adherence for high-risk, high-value, and long-term therapies. In doing so, Validose aims to accelerate an exponential reduction in prescription drug abuse through present and future risk management. Validose will enter the market first for intranasal drug applications, then expanding to sublingual, transdermal, oral, and other delivery methods through key packaging and pharmaceutical partnerships.